These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 23467121)

  • 1. Enzalutamide (Xtandi) for prostate cancer.
    Med Lett Drugs Ther; 2013 Mar; 55(1411):e20. PubMed ID: 23467121
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of enzalutamide in the treatment of castration-resistant prostate cancer.
    Rawlinson A; Mohammed A; Miller M; Kunkler R
    Future Oncol; 2012 Sep; 8(9):1073-81. PubMed ID: 23030482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzalutamide for the treatment of castration-resistant prostate cancer.
    Ha YS; Goodin S; DiPaola RS; Kim IY
    Drugs Today (Barc); 2013 Jan; 49(1):7-13. PubMed ID: 23362491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect and adverse event of enzalutamide and abiraterone in prostate cancer].
    Kosaka T; Oya M
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():308-12. PubMed ID: 25831773
    [No Abstract]   [Full Text] [Related]  

  • 5. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
    Armstrong AJ; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Shore ND; Rosbrook B; Sugg J; Baron B; Chen L; Stenzl A
    J Clin Oncol; 2019 Nov; 37(32):2974-2986. PubMed ID: 31329516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NICE guidance on enzalutamide for metastatic hormone-relapsed prostate cancer.
    Elsada A; Pearce F; George E; Adler A
    Lancet Oncol; 2014 Sep; 15(10):1058-9. PubMed ID: 25328938
    [No Abstract]   [Full Text] [Related]  

  • 7. Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer.
    Hoffman-Censits J; Kelly WK
    Clin Cancer Res; 2013 Mar; 19(6):1335-9. PubMed ID: 23300275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer: an enzalutamide antiandrogen withdrawal syndrome.
    Phillips R
    Nat Rev Urol; 2014 Jul; 11(7):366. PubMed ID: 24960596
    [No Abstract]   [Full Text] [Related]  

  • 9. The Combination of Enzalutamide and Opioids: A Painful Pitfall?
    Benoist GE; van Oort IM; Burger DM; Koch BCP; Mehra N; van Erp NP
    Eur Urol; 2019 Feb; 75(2):351-352. PubMed ID: 30245086
    [No Abstract]   [Full Text] [Related]  

  • 10. Secondary hormone therapy for castration-resistant prostate cancer.
    Taplin ME
    Oncology (Williston Park); 2013 May; 27(5):371-2. PubMed ID: 25184257
    [No Abstract]   [Full Text] [Related]  

  • 11. Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape.
    Kinsey EN; Zhang T; Armstrong AJ
    Cancer J; 2020; 26(1):64-75. PubMed ID: 31977388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of statins on advanced prostate cancer patients with androgen deprivation therapy or abiraterone/enzalutamide: A systematic review and meta-analysis.
    Yang H; Pang L; Hu X; Wang W; Xu B; Zhang X; Liu L
    J Clin Pharm Ther; 2020 Jun; 45(3):488-495. PubMed ID: 31951037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
    Rodriguez-Vida A; Galazi M; Rudman S; Chowdhury S; Sternberg CN
    Drug Des Devel Ther; 2015; 9():3325-39. PubMed ID: 26170619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The unaffordable cost of M&A-driven drug prices.
    Goozner M
    Mod Healthc; 2016 Oct; 46(35):24. PubMed ID: 30452799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Management of enzalutamide, a new hormonal therapy].
    Beuzeboc P; Benderra MA; de La Motte Rouge T
    Bull Cancer; 2014 Jan; 101(1):107-12. PubMed ID: 24491670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revisiting the ultimate target of treatment for prostate cancer.
    Dahut WL; Madan RA
    Lancet; 2010 Apr; 375(9724):1409-10. PubMed ID: 20398924
    [No Abstract]   [Full Text] [Related]  

  • 17. Enzalutamide: A Review in Castration-Resistant Prostate Cancer.
    Scott LJ
    Drugs; 2018 Dec; 78(18):1913-1924. PubMed ID: 30535926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Antiandrogen Compounds Compared to Docetaxel for Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis.
    Marchioni M; Di Nicola M; Primiceri G; Novara G; Castellan P; Paul AK; Veccia A; Autorino R; Cindolo L; Schips L
    J Urol; 2020 Apr; 203(4):751-759. PubMed ID: 31689158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis.
    Zhu J; Liao R; Su C; Liang D; Wu J; Qiu K; Li J
    Expert Rev Anticancer Ther; 2018 Feb; 18(2):193-198. PubMed ID: 29257709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer.
    Murga JD; Moorji SM; Han AQ; Magargal WW; DiPippo VA; Olson WC
    Prostate; 2015 Feb; 75(3):242-54. PubMed ID: 25327687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.